New antibody drug aims to ease endometriosis pain in major trial
Symptom relief
Not yet recruiting
This Phase 3 trial tests HMI-115, a monoclonal antibody, in 540 women with moderate to severe endometriosis pain. Participants receive either the drug or a placebo for 24 weeks, with a 28-week extension. The goal is to see if HMI-115 reduces menstrual and pelvic pain better than …
Phase: PHASE3 • Sponsor: Hope Medicine (Nanjing) Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC